Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
NCT ID: NCT00078117
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
516 participants
INTERVENTIONAL
2003-06-30
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
NCT00032968
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
NCT00032955
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2
NCT00000327
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1
NCT00000326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects meet DSM-IV criteria for opiate dependence, are medically and psychiatrically stable, and do not have a current history of benzodiazepine dependence abuse, dependence, or treatment
15 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of California, Los Angeles
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Walter Ling, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Addiction Research & Treatment Services (ARTS)
Denver, Colorado, United States
Denver Health & Hospitals Authority
Denver, Colorado, United States
Hartford Dispensary
Hartford, Connecticut, United States
Connecticut Counseling Centers
Waterbury, Connecticut, United States
LI Jewish Health System
Glen Oaks, New York, United States
New York VA Medical Center
New York, New York, United States
South Light-Wakeview Clinic
Raleigh, North Carolina, United States
Coastal Horizons Center, Inc.
Wilmington, North Carolina, United States
CODA
Portland, Oregon, United States
Norfolk CSB
Norfolk, Virginia, United States
Providence Behavioral Health Services
Everett, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013 Jan-Feb;7(1):33-8. doi: 10.1097/ADM.0b013e318277e92e.
Hillhouse M, Canamar CP, Ling W. Predictors of outcome after short-term stabilization with buprenorphine. J Subst Abuse Treat. 2013 Mar;44(3):336-42. doi: 10.1016/j.jsat.2012.08.016. Epub 2012 Sep 26.
Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23. doi: 10.3109/00952990.2011.596982.
Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009 Feb;104(2):256-65. doi: 10.1111/j.1360-0443.2008.02455.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CTN-0003-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.